BRSYF: AI 评分 62/100 — AI 分析 (4月 2026)

BrainsWay Ltd. specializes in noninvasive neurostimulation treatments for mental health disorders, utilizing its Deep Transcranial Magnetic Stimulation (dTMS) platform. The company serves doctors, hospitals, and medical centers, primarily in psychiatry, across the United States, Europe, and Israel.

Key Facts: AI Score: 62/100 Sector: Healthcare

公司概况

概要：

BrainsWay Ltd. is a medical device company focused on developing and commercializing its Deep Transcranial Magnetic Stimulation (dTMS) platform for treating various mental health disorders. With a presence in the US, Europe, and Israel, BrainsWay caters to the psychiatry sector, offering non-invasive neurostimulation solutions.

BRSYF是做什么的？

Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay Ltd. is a medical device company specializing in the development and commercialization of noninvasive neurostimulation treatments for mental health disorders. The company's core technology is the Deep Transcranial Magnetic Stimulation (dTMS) platform, which is designed to treat a range of conditions, including major depressive disorder (MDD), anxious depression, obsessive-compulsive disorder (OCD), and smoking addiction. BrainsWay's dTMS system is also being explored for potential applications in bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay primarily serves doctors, hospitals, and medical centers in the field of psychiatry. The company has expanded its reach to the United States, Europe, and Israel, establishing a global presence in the mental health treatment market. BrainsWay's focus on non-invasive solutions positions it within a growing segment of the medical device industry, driven by increasing demand for effective and accessible mental health treatments.

BRSYF的投资论点是什么？

BrainsWay Ltd. presents a focused investment opportunity within the neurostimulation segment of the medical device industry. The company's dTMS technology addresses a significant market need for non-invasive mental health treatments. With a P/E ratio of 64.24 and a profit margin of 14.6%, BrainsWay demonstrates profitability, although the P/E suggests a high valuation. The company's gross margin of 75.4% indicates strong pricing power and efficient operations. Growth catalysts include expanding applications of dTMS technology and increasing adoption in key markets. However, potential risks include competition from other neurostimulation technologies and the need for continued clinical validation of dTMS efficacy across various indications.

BRSYF在哪个行业运营？

BrainsWay operates in the medical device industry, specifically within the neurostimulation market. This market is driven by increasing prevalence of mental health disorders and growing demand for non-invasive treatment options. The competitive landscape includes companies offering alternative neurostimulation technologies and pharmaceutical treatments. BrainsWay's dTMS platform differentiates itself through its deep stimulation capabilities and expanding clinical applications. The global market for neurostimulation devices is projected to grow, driven by technological advancements and increasing awareness of mental health issues.

Medical - Devices

Healthcare

BRSYF有哪些增长机遇？

Expanding dTMS Applications: BrainsWay has the opportunity to expand the applications of its dTMS technology beyond its current indications, such as MDD and OCD. Exploring new therapeutic areas like Alzheimer's disease, autism, and chronic pain could significantly increase the addressable market. Clinical trials and research collaborations will be crucial for validating the efficacy of dTMS in these new areas. Success in these areas could open up new revenue streams and establish BrainsWay as a leader in non-invasive treatment options for a wider range of neurological and psychiatric disorders.
Geographic Expansion: BrainsWay can pursue growth by expanding its geographic presence, particularly in underserved markets. Entering new regions in Asia, South America, and Africa could provide access to a large patient population. This expansion would require establishing partnerships with local distributors and healthcare providers, as well as obtaining regulatory approvals in each new market. Successful geographic expansion could diversify BrainsWay's revenue streams and reduce its reliance on existing markets.
Strategic Partnerships and Acquisitions: BrainsWay can explore strategic partnerships and acquisitions to enhance its technology and market reach. Collaborating with other medical device companies or research institutions could accelerate the development of new dTMS applications. Acquiring complementary technologies or companies could expand BrainsWay's product portfolio and market share. These partnerships and acquisitions could provide access to new expertise, resources, and distribution channels.
Increased Adoption in Psychiatry: BrainsWay can focus on increasing the adoption of its dTMS system among psychiatrists and mental health professionals. This can be achieved through targeted marketing campaigns, educational programs, and clinical training. Demonstrating the clinical and economic benefits of dTMS compared to traditional treatments, such as medication and electroconvulsive therapy (ECT), will be essential for driving adoption. Increased adoption in psychiatry could lead to a significant increase in BrainsWay's revenue and market share.
Development of Next-Generation dTMS Technology: BrainsWay can invest in the development of next-generation dTMS technology to improve its efficacy, safety, and ease of use. This could involve developing new coil designs, stimulation protocols, and software algorithms. Incorporating advanced technologies, such as artificial intelligence and machine learning, could further enhance the performance of the dTMS system. The development of next-generation technology could maintain BrainsWay's competitive advantage and attract new customers.

Market capitalization of $0.47 billion indicates a mid-sized company in the medical device sector.
P/E ratio of 64.24 suggests investors have high expectations for future earnings growth.
Profit margin of 14.6% demonstrates the company's ability to generate profits from its revenue.
Gross margin of 75.4% highlights efficient cost management and strong pricing power.
Beta of 1.46 suggests the stock is more volatile than the overall market.

BRSYF提供哪些产品和服务？

Develops Deep Transcranial Magnetic Stimulation (dTMS) technology.
Offers noninvasive neurostimulation treatments for mental health disorders.
Provides dTMS systems for the treatment of major depressive disorders.
Addresses anxious depression and obsessive-compulsive disorders.
Offers solutions for smoking addiction.
Explores applications in bipolar disorders, PTSD, and schizophrenia.
Investigates dTMS for Alzheimer's disease, autism, and chronic pain.
Serves doctors, hospitals, and medical centers in psychiatry.

BRSYF如何赚钱？

Sells Deep Transcranial Magnetic Stimulation (dTMS) systems to medical facilities.
Generates revenue through the sale of disposable treatment coils.
Provides training and support services for dTMS system users.
Pursues research and development collaborations to expand dTMS applications.

Psychiatrists and mental health professionals.
Hospitals and medical centers.
Research institutions.
Patients seeking noninvasive mental health treatments.

Proprietary Deep Transcranial Magnetic Stimulation (dTMS) technology.
Established clinical evidence supporting the efficacy of dTMS.
Strong relationships with key opinion leaders in psychiatry.
Regulatory approvals for dTMS in major markets.

什么因素可能推动BRSYF股价上涨？

Ongoing: Expansion of dTMS applications to new therapeutic areas.
Ongoing: Geographic expansion into underserved markets.
Upcoming: Potential strategic partnerships and acquisitions.
Ongoing: Increased adoption of dTMS in psychiatry.
Ongoing: Development of next-generation dTMS technology.

BRSYF的主要风险是什么？

Potential: Competition from alternative neurostimulation technologies.
Potential: Regulatory changes affecting medical device approvals.
Potential: Reimbursement challenges from healthcare providers.
Potential: Economic downturns impacting healthcare spending.
Ongoing: Dependence on the success of dTMS technology.

BRSYF的核心优势是什么？

Proprietary Deep TMS technology.
Clinical evidence supporting efficacy.
Established presence in key markets.
High gross margin.

BRSYF的劣势是什么？

Limited product portfolio.
Reliance on dTMS technology.
Relatively small market capitalization.
High P/E ratio.

BRSYF有哪些机遇？

Expanding dTMS applications.
Geographic expansion.
Strategic partnerships and acquisitions.
Increased adoption in psychiatry.

BRSYF面临哪些威胁？

Competition from alternative neurostimulation technologies.
Regulatory changes.
Reimbursement challenges.
Economic downturns.

BRSYF的竞争对手是谁？

Bachem Holding AG — Focuses on peptides and oligonucleotides. — (BCCOY)
Coloplast A/S — Offers products for ostomy, continence, wound, and skin care. — (CLLKF)
Cyberdyne Inc. — Develops and manufactures medical cybernics technology. — (CYBQF)
Cyberdyne Inc. — Develops and manufactures medical cybernics technology. — (CYBQY)
Genfit SA — Focuses on the discovery and development of therapeutic solutions. — (GNFTF)

Key Metrics

MoonshotScore: 62/100

Company Profile

CEO: Hadar Levy
Headquarters: Jerusalem, IL
Employees: 120
Founded: 2011

AI Insight

AI analysis pending for BRSYF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does BrainsWay Ltd. do?

BrainsWay Ltd. develops and commercializes Deep Transcranial Magnetic Stimulation (dTMS) systems for the treatment of mental health disorders. Their primary product is a non-invasive neurostimulation device used to treat conditions like major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company's business model revolves around selling these dTMS systems to hospitals, clinics, and psychiatric practices, along with providing ongoing support and training. BrainsWay operates in the growing market for non-pharmacological treatments for mental health, offering an alternative to traditional medication-based approaches.

What do analysts say about BRSYF stock?

As of 2026-03-17, a comprehensive analyst consensus for BRSYF is pending AI analysis. Key valuation metrics to consider include the company's P/E ratio of 64.24, which suggests a premium valuation. Growth considerations revolve around the expansion of dTMS applications and geographic reach. Investors should monitor analyst reports for updates on revenue projections, earnings estimates, and target prices. However, it's essential to conduct independent research and consider individual investment objectives before making any decisions.

What are the main risks for BRSYF?

The main risks for BrainsWay Ltd. include competition from other neurostimulation technologies, such as transcranial direct current stimulation (tDCS) and vagus nerve stimulation (VNS). Regulatory changes and reimbursement challenges could also impact the company's ability to commercialize its dTMS system. Additionally, the success of BrainsWay is highly dependent on the continued clinical validation and adoption of its dTMS technology. Economic downturns could affect healthcare spending and reduce demand for non-essential medical treatments.